Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Can a Calorie-Restricted Diet Improve Long-Term Progressive Kidney Function Decline?
The Safety and Efficacy of Next-Generation G7 CGM Over G6
A1c, Sleep Quality and Duration in Prediabetes Patients
Insulin Abnormalities in Metabolic Syndrome and T2D
Rise in Cost for Treating Type 2 Diabetes Medicare Beneficiaries
Letter from the Editor
Over the past few years the use of CGMs has increased significantly. More and more providers, insurers and benefit managers have seen the value of their use. Where we only had individual readings and A1c to gauge overall management success, the use of CGMs has allowed “Time in Range” to become a measurement that is even more important in overall management. These devices have also made it possible for “smart pumps” to predict glucose trends and adjust insulin accordingly.
The Dexcom G6 has been the “Cadillac” of stand alone devices, and this week our intern Janet Falade, PharmD Candidate, South College School of Pharmacy, brings a study on the new G7 device, and why both prescribers and patients will want to use this new device.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: Coming -- The Next Generation of CGM
See article #3.
TOP STORIES — Diabetes News and Research
Studies have found that there may be a benefit in implementing a calorie-restricted diet in patients with type 2 diabetes to improve glomerular hyperfiltration.
The seventh-generation (G7) continuous glucose monitor provides accurate and safe glucose readings during 10.5 days of use among adults that have diabetes.
Data suggest that fewer than twenty percent of patients with type 2 diabetes are lowering their risk of heart disease, prompting prominent doctors to demand immediate action.
There is growing evidence suggesting that the quality and duration of sleep may contribute to the risk of prediabetes progressing to type 2 diabetes.
Insulin resistance presents a biomarker for poor metabolic health.
A data-driven-approach study was conducted to identify the cost of spending for long-term care patients with diabetes by accessing data from Medicare Fee-for-Service beneficiaries, including Medicare parts A, B, and D for two years.
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:
Betsy Adegborioye, PharmD Candidate 2022, South College School of Pharmacy
Janet Falade, PharmD Candidate, South College School of Pharmacy
Milane Kenguim, PharmD Candidate, South College School of Pharmacy
Aleksandra Kusic, PharmD Candidate, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences
Amanda Roberts, PharmD Candidate, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences Institute of Public Health
Emily Walser, PharmD Candidate 2022, Lake Erie College of Osteopathic Medicine, College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com